These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

358 related articles for article (PubMed ID: 34142533)

  • 1. [Development of antiviral drugs based on inhibitors of the SARS-COV-2 main protease].
    Sulimov AV; Shikhaliev KS; Pyankov OV; Shcherbakov DN; Chirkova VY; Ilin IS; Kutov DC; Tashchilova AS; Krysin MY; Krylskiy DV; Stolpovskaya NV; Volosnikova EA; Belenkaya SV; Sulimov VB
    Biomed Khim; 2021 May; 67(3):259-267. PubMed ID: 34142533
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New Chemicals Suppressing SARS-CoV-2 Replication in Cell Culture.
    Sulimov A; Ilin I; Kutov D; Shikhaliev K; Shcherbakov D; Pyankov O; Stolpovskaya N; Medvedeva S; Sulimov V
    Molecules; 2022 Sep; 27(17):. PubMed ID: 36080498
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimization Rules for SARS-CoV-2 M
    Stoddard SV; Stoddard SD; Oelkers BK; Fitts K; Whalum K; Whalum K; Hemphill AD; Manikonda J; Martinez LM; Riley EG; Roof CM; Sarwar N; Thomas DM; Ulmer E; Wallace FE; Pandey P; Roy S
    Viruses; 2020 Aug; 12(9):. PubMed ID: 32859008
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In silico identification of potential inhibitors of key SARS-CoV-2 3CL hydrolase (Mpro) via molecular docking, MMGBSA predictive binding energy calculations, and molecular dynamics simulation.
    Choudhary MI; Shaikh M; Tul-Wahab A; Ur-Rahman A
    PLoS One; 2020; 15(7):e0235030. PubMed ID: 32706783
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In silico prediction of potential inhibitors for the main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing.
    Kumar Y; Singh H; Patel CN
    J Infect Public Health; 2020 Sep; 13(9):1210-1223. PubMed ID: 32561274
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Maurya AK; Mishra N
    J Biomol Struct Dyn; 2021 Nov; 39(18):7306-7321. PubMed ID: 32835632
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In Silico Evaluation of the Effectivity of Approved Protease Inhibitors against the Main Protease of the Novel SARS-CoV-2 Virus.
    Eleftheriou P; Amanatidou D; Petrou A; Geronikaki A
    Molecules; 2020 May; 25(11):. PubMed ID: 32485894
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of potent inhibitors for SARS-CoV-2's main protease by ligand-based/structure-based virtual screening, MD simulations, and binding energy calculations.
    Abu-Saleh AAA; Awad IE; Yadav A; Poirier RA
    Phys Chem Chem Phys; 2020 Oct; 22(40):23099-23106. PubMed ID: 33025993
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anthocyanin derivatives as potent inhibitors of SARS-CoV-2 main protease: An in-silico perspective of therapeutic targets against COVID-19 pandemic.
    Fakhar Z; Faramarzi B; Pacifico S; Faramarzi S
    J Biomol Struct Dyn; 2021 Oct; 39(16):6171-6183. PubMed ID: 32741312
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of a Fluorescence-Based, High-Throughput SARS-CoV-2 3CL
    Froggatt HM; Heaton BE; Heaton NS
    J Virol; 2020 Oct; 94(22):. PubMed ID: 32843534
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biochemical screening for SARS-CoV-2 main protease inhibitors.
    Coelho C; Gallo G; Campos CB; Hardy L; Würtele M
    PLoS One; 2020; 15(10):e0240079. PubMed ID: 33022015
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular Binding Mechanism and Pharmacology Comparative Analysis of Noscapine for Repurposing against SARS-CoV-2 Protease.
    Kumar N; Sood D; van der Spek PJ; Sharma HS; Chandra R
    J Proteome Res; 2020 Nov; 19(11):4678-4689. PubMed ID: 32786685
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Virtual screening, ADME/T, and binding free energy analysis of anti-viral, anti-protease, and anti-infectious compounds against NSP10/NSP16 methyltransferase and main protease of SARS CoV-2.
    Maurya SK; Maurya AK; Mishra N; Siddique HR
    J Recept Signal Transduct Res; 2020 Dec; 40(6):605-612. PubMed ID: 32476594
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiviral peptides inhibiting the main protease of SARS-CoV-2 investigated by computational screening and in vitro protease assay.
    Stewart J; Shawon J; Ali MA; Williams B; Shahinuzzaman ADA; Rupa SA; Al-Adhami T; Jia R; Bourque C; Faddis R; Stone K; Sufian MA; Islam R; McShan AC; Rahman KM; Halim MA
    J Pept Sci; 2024 Apr; 30(4):e3553. PubMed ID: 38031661
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clean Grinding Technique: A Facile Synthesis and In Silico Antiviral Activity of Hydrazones, Pyrazoles, and Pyrazines Bearing Thiazole Moiety against SARS-CoV-2 Main Protease (M
    Abu-Melha S; Edrees MM; Riyadh SM; Abdelaziz MR; Elfiky AA; Gomha SM
    Molecules; 2020 Oct; 25(19):. PubMed ID: 33036293
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Virtual Double-System Single-Box: A Nonequilibrium Alchemical Technique for Absolute Binding Free Energy Calculations: Application to Ligands of the SARS-CoV-2 Main Protease.
    Macchiagodena M; Pagliai M; Karrenbrock M; Guarnieri G; Iannone F; Procacci P
    J Chem Theory Comput; 2020 Nov; 16(11):7160-7172. PubMed ID: 33090785
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An investigation into the identification of potential inhibitors of SARS-CoV-2 main protease using molecular docking study.
    Das S; Sarmah S; Lyndem S; Singha Roy A
    J Biomol Struct Dyn; 2021 Jun; 39(9):3347-3357. PubMed ID: 32362245
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In silico drug discovery of major metabolites from spices as SARS-CoV-2 main protease inhibitors.
    Ibrahim MAA; Abdelrahman AHM; Hussien TA; Badr EAA; Mohamed TA; El-Seedi HR; Pare PW; Efferth T; Hegazy MF
    Comput Biol Med; 2020 Nov; 126():104046. PubMed ID: 33065388
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of a simple, interpretable and easily transferable QSAR model for quick screening antiviral databases in search of novel 3C-like protease (3CLpro) enzyme inhibitors against SARS-CoV diseases.
    Kumar V; Roy K
    SAR QSAR Environ Res; 2020 Jul; 31(7):511-526. PubMed ID: 32543892
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting SARS-CoV-2 Main Protease (MPro) with Kinase Inhibitors: A Promising Approach for Discovering Antiviral and Anti-inflammatory Molecules against SARS-CoV-2.
    Anton DB; Galvez Bulhões Pedreira J; Zvirtes ML; Laufer SA; Ducati RG; Goettert M; Saraiva Macedo Timmers LF
    J Chem Inf Model; 2023 Jul; 63(13):4138-4146. PubMed ID: 37329322
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.